Log in to your Inderes Free account to see all free content on this page.
Intervacc
3.5 SEK -0.57%1 investor is following this company
Intervacc is a biotechnology company. The company develops vaccines within animal health care. There is a special focus on the treatment of infections caused by streptococci and staphylococci. The business is run on the basis of various subsidiaries, each with a business focus. Sales take place mainly in the Nordic and Baltic countries. The company's head office is located in Hägersten.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
IVACC
Daily low / high price
3.42 / 3.56
SEK
Market cap
265.08M SEK
Turnover
171.31K SEK
Volume
49K
Financial calendar
Interim report
29.08.2024
Interim report
14.11.2024
Annual report
13.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Swedbank Robur Småbolagsfond | 6.8 % | 6.8 % |
Fjärde AP-fonden | 5.0 % | 5.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Report from Annual General Meeting in Intervacc
Intervacc: Interim report January - March 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio